Loading institutional data...
Loading institutional data...
Held by 650 of 6,047 reporting institutions (98th percentile) — extremely crowded.
Data as of Q2 2026
Loading snapshot...
Loading financials...
Loading valuation...
Loading quality & risk...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Loading ownership map...
Loading crowding analysis...
Loading conviction analysis...
Loading buy/sell flow...
Loading ownership trends...
Loading top holders...
Loading top holders...
Solve the discounted cash flow backwards, then stress-test the assumptions.
To be worth $143.74 today, the market must believe free cash flow compounds 4.6%/yr for a decade (off $573.8M normalized FCF).
The market's 4.6% is more conservative than its 9-yr track record.
2-stage DCF · 0.07B shares · net debt -$1.09B
mean 25.3% · volatility σ 56% · implied rate exceeded in 5/9 yrs
Central path = implied 4.6%/yr growth; shaded band = ±1σ (56%) of this company's historical FCF volatility, widening with time. The wider the band, the less certain the growth.
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
Is the value real, and is the business safe? Academic scores + earnings quality + solvency, from SEC filings.
6/8 of the 9 checks — 1 couldn't be scored (see above), so the score is out of the 8 with data.
Safe > 2.99 · grey 1.81–2.99 · distress < 1.81
Eight indices comparing this year to last (receivables, margins, asset quality, growth, accruals, leverage). Above −1.78 suggests possible manipulation; below −2.22 is clean.
A screen, not proof — high growth alone can raise it.
Earnings are backed by cash (FCF ≥ net income) — high quality. Lower/negative accruals = higher quality (Sloan).
Coverage data unavailable.
F-Score (0–9 fundamental momentum), Altman Z (distress risk), and Beneish M (earnings-manipulation screen) are academic models computed from the SEC filings. Screens and context — educational, not recommendations.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $465.9M buybacks = $465.9M returned on $490.8M FCF.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A balanced mix of reinvestment and shareholder returns.
Modest payoff on reinvested capital. Current ROIC on all capital: 10%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest expense isn't separately reported — often netted into “other income (expense), net.”
Cash vs short-term debt unavailable.
Short-term / long-term split not separately reported.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-10-02
Nothing notable to watch.
No material risks flagged.
Where each multiple sits in its own 14-yr range · 2th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 14-yr history.
Is the profit real, and how strong is the balance sheet?
FY2025 · every deduction from revenue to net income
DuPont — the three levers
Returns are margin-driven, not leverage-driven — higher quality.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
Profit and sales moved in opposite directions this year.
Each line as % of revenue — the trend in color
| % of revenue | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 26.4 | 27.5 | 28.7 | 25.7 | 29.5 | 29.9 | 30.0 | 32.8 |
| Gross Profit | 73.6 | 72.5 | 71.3 | 74.3 | 70.5 | 70.1 | 70.0 | 67.2 |
| R&D | 6.6 | 6.5 | 7.1 | 6.3 | 8.2 | 9.0 | 9.1 | 9.2 |
| SG&A | 43.3 | 44.5 | 48.6 | 43.2 | 44.8 | 44.1 | 44.1 | 43.5 |
| Operating Income | 23.7 | 22.5 | 15.7 | 24.7 | 17.2 | 16.7 | 15.2 | 13.5 |
| Income Tax | 2.9 | 4.7 | -56.5 | 6.1 | 6.4 | 5.1 | 4.7 | 4.3 |
| Net Income | 20.4 | 18.4 | 71.8 | 19.5 | 9.7 | 11.5 | 10.5 | 10.2 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on ALGN: price, valuation, headline fundamentals, and an auto-generated scorecard from SEC filings. Flags are rule-based signals, not recommendations.
EOD close · as of 2026-10-02
How a revenue dollar becomes profit — FY2025
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it. This year they exceeded net income, so the ribbons are capped at earnings and understate what was actually returned.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.03B 100.0% | $4.00B 100.0% | $3.86B 100.0% | $3.73B 100.0% | $3.95B 100.0% | $2.47B 100.0% | $2.41B 100.0% | $1.97B 100.0% | $1.47B 100.0% | $1.08B 100.0% |
| Cost of Revenue | $1.32B 32.8% | $1.20B 30.0% | $1.16B 29.9% | $1.10B 29.5% | $1.02B 25.7% | $708.7M 28.7% | $662.9M 27.5% | $518.6M 26.4% | $356.5M 24.2% | $264.6M 24.5% |
| Gross Profit | $2.71B 67.2% | $2.80B 70.0% | $2.71B 70.1% | $2.63B 70.5% | $2.94B 74.3% | $1.76B 71.3% | $1.74B 72.5% | $1.45B 73.6% | $1.12B 75.8% | $815.3M 75.5% |
| Research & Development | $369.9M 9.2% | $364.2M 9.1% | $346.8M 9.0% | $305.3M 8.2% | $250.3M 6.3% | $175.3M 7.1% | $157.4M 6.5% | $128.9M 6.6% | $97.6M 6.6% | $75.7M 7.0% |
| Selling, General & Admin | $1.76B 43.5% | $1.76B 44.1% | $1.70B 44.1% | $1.67B 44.8% | $1.71B 43.2% | $1.20B 48.6% | $1.07B 44.5% | $852.4M 43.3% | $665.8M 45.2% | $490.7M 45.4% |
| Total Operating Expenses | $2.17B 53.7% | $2.19B 54.8% | $2.06B 53.4% | $1.99B 53.3% | $1.96B 49.6% | $1.38B 55.7% | $1.20B 49.9% | $981.3M 49.9% | $763.3M 51.8% | $566.4M 52.4% |
| Operating Income | $545.8M 13.5% | $607.6M 15.2% | $643.3M 16.7% | $642.6M 17.2% | $976.4M 24.7% | $387.2M 15.7% | $542.5M 22.5% | $466.6M 23.7% | $353.6M 24.0% | $248.9M 23.1% |
| Interest & Investment Income | $16.0M 0.4% | $20.2M 0.5% | $17.3M 0.4% | $5.4M 0.1% | $3.1M 0.1% | $3.1M 0.1% | $12.5M 0.5% | $8.6M 0.4% | — | — |
| Other Income (Expense), net | $23.5M 0.6% | -$18.9M -0.5% | -$19.4M -0.5% | -$48.9M -1.3% | $32.9M 0.8% | -$11.3M -0.5% | $7.7M 0.3% | -$8.5M -0.4% | $4.2M 0.3% | -$10.6M -1.0% |
| Pretax Income | $585.3M 14.5% | $609.0M 15.2% | $641.2M 16.6% | $599.1M 16.0% | $1.01B 25.6% | $378.9M 15.3% | $562.7M 23.4% | $466.7M 23.7% | $364.8M 24.8% | $242.6M 22.5% |
| Income Tax Expense | $174.9M 4.3% | $187.6M 4.7% | $196.2M 5.1% | $237.5M 6.4% | $240.4M 6.1% | -$1.40B -56.5% | $112.3M 4.7% | $57.7M 2.9% | $130.2M 8.8% | $51.2M 4.7% |
| Net Income | $410.0M 10.2% | $421.0M 10.5% | $445.0M 11.5% | $362.0M 9.7% | $772.0M 19.5% | $1.78B 71.8% | $442.8M 18.4% | $400.2M 20.4% | $231.4M 15.7% | $189.7M 17.6% |
| Per Share | ||||||||||
| EPS (Basic) | $5.66 | $5.63 | $5.82 | $4.62 | $9.78 | $22.55 | $5.57 | $5.00 | $2.89 | $2.38 |
| EPS (Diluted) | $5.65 | $5.62 | $5.81 | $4.61 | $9.69 | $22.41 | $5.53 | $4.92 | $2.83 | $2.33 |
| Weighted Avg Shares (Basic) | 72.5M | 74.9M | 76.4M | 78.2M | 78.9M | 78.8M | 79.4M | 80.1M | 80.1M | 79.9M |
| Weighted Avg Shares (Diluted) | 72.6M | 75.0M | 76.6M | 78.4M | 79.7M | 79.2M | 80.1M | 81.4M | 81.8M | 81.5M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
Ranked against 1094 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-06-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LLY | $1.02T | 49.8× | — | 15.6× | 44.7% | 83.0% | 31.7% | 77.8% | 29.9% | — | 4,500 |
| JNJ | $617.0B | 23.2× | 19.6× | 6.5× | 6.0% | 67.9% | 28.5% | 32.9% | 20.7% | 0.9× | 4,554 |
| ABBV | $464.4B | 111.4× | 33.2× | 7.6× | 8.6% | 70.2% | 6.9% | -129% | 6.6% | 3.9× | 4,062 |
| MRK | $356.0B | 19.8× | — | 5.5× | 1.3% | 74.8% | 28.1% | 34.7% | 17.9% | — | 3,683 |
| UNH | $333.8B | 28.1× | 19.4× | 0.8× | 11.8% | 88.7% | 2.7% | 12.0% | 6.8% | 2.7× | 3,258 |
| AZN | $243.3B | — | — | — | — | — | — | — | — | — | 1,402 |
| TMO | $242.1B | 36.9× | 31.3× | 5.4× | 3.9% | — | 15.0% | 12.6% | 7.0% | 3.7× | 2,528 |
| AMGN | $217.9B | 28.3× | 18.5× | 5.9× | 10.0% | 67.2% | 21.0% | 89.1% | 12.2% | 3.2× | 3,070 |
| GILD | $179.5B | 21.4× | 19.7× | 6.1× | 2.4% | 78.8% | 28.9% | 37.5% | 17.9% | 2.4× | 2,216 |
| ABT | $168.7B | 26.2× | 18.3× | 3.8× | 5.7% | 56.4% | 14.7% | 12.5% | 10.0% | 0.5× | 2,876 |
| PFE | $158.5B | 20.4× | — | 2.5× | -1.6% | 74.3% | 12.4% | 9.0% | 5.1% | — | 2,748 |
| DHR | $150.5B | 42.4× | 31.1× | 6.1× | 2.9% | 59.1% | 14.7% | 6.9% | 5.1% | 3.4× | 2,050 |
| ISRG | $140.4B | 49.8× | 38.7× | 13.9× | 20.5% | 66.0% | 28.4% | 16.0% | 16.0% | -0.9× | 2,165 |
| VRTX | $127.9B | 33.0× | 28.0× | 10.7× | 8.9% | 86.2% | 32.9% | 21.2% | 21.2% | -1.2× | 1,689 |
| BMY | $124.9B | 17.7× | — | 2.6× | -0.2% | 71.1% | 14.6% | 38.2% | 11.1% | — | 2,451 |
| CVS | $110.6B | 62.2× | 11.0× | 0.3× | 7.8% | 45.0% | 0.4% | 2.4% | 2.4% | -0.9× | 2,009 |
| MDT | $110.5B | 23.2× | 14.5× | 3.0× | 8.4% | 65.0% | 13.2% | 9.7% | 6.2% | 2.8× | 2,050 |
| SYK | $105.6B | 32.8× | 18.2× | 4.2× | 11.2% | 64.0% | 12.9% | 14.5% | 8.5% | 1.8× | 2,183 |
| MCK | $105.2B | 23.5× | 16.6× | 0.3× | 12.4% | 3.6% | 1.2% | -219% | 109% | 0.4× | 1,943 |
| HCA | $92.4B | 15.1× | — | 1.2× | 7.1% | — | 9.0% | -113% | 16.8% | — | 1,288 |
| ELV | $83.8B | 15.3× | 14.4× | 0.4× | 12.5% | 89.4% | 2.8% | 12.9% | 7.6% | 2.9× | 1,560 |
| MRNA | $75.9B | — | — | 39.0× | -39.9% | 55.3% | -145% | -32.6% | -30.5% | — | 774 |
| REGN | $75.7B | 17.7× | 18.1× | 5.3× | 1.0% | — | 31.4% | 14.4% | 13.6% | -0.3× | 1,291 |
| CI | $71.5B | 12.2× | 8.0× | 0.3× | 11.2% | 21.8% | 2.2% | 14.3% | 8.1% | 2.0× | 1,638 |
| BSX | $61.7B | 22.0× | 12.1× | 3.1× | 19.9% | 69.0% | 14.4% | 11.9% | 11.8% | -0.3× | 1,430 |
| ALGN | $10.2B | 25.4× | 11.6× | 2.5× | 0.9% | 67.2% | 10.2% | 10.1% | 10.1% | -1.4× | 650 |
Peers = companies sharing ALGN's sector (Healthcare) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.